Cilostazol Dosage and Administration

Standard Dosage

• The American College of Cardiology recommends a dosage of 100 mg of cilostazol orally twice a day for the treatment of intermittent claudication in patients with peripheral arterial disease, which has been shown to improve maximum walking distance by 40-60% compared to placebo after 12-24 weeks of therapy 1, 2, 3
• A dosage of 100 mg twice a day is significantly more effective than a dosage of 50 mg twice a day in comparative studies 2, 3

Contraindications

• Cilostazol is absolutely contraindicated in patients with heart failure of any severity, as recommended by the American College of Cardiology 1, 2, 3, 4
• The FDA has issued a black box warning prohibiting its use in patients with heart failure due to the increased risk of mortality associated with type III phosphodiesterase inhibitors 2, 3, 4

Evaluation of Treatment Response

• The American Heart Association suggests evaluating patient tolerance to cilostazol 2-4 weeks after initiation of treatment, although this specific guideline is from Praxis Medical Insights, a similar recommendation may be found from other societies 5
• It is recommended to determine the clinical benefit within 3-6 months to decide whether to continue long-term therapy, however this is based on a guideline from Praxis Medical Insights, and a similar recommendation from the American College of Cardiology or other societies may be more relevant 5

Common Adverse Effects

• Common side effects include headache, diarrhea, abnormal stools, palpitations, and dizziness, as reported in studies published in Circulation 2, 3

Cilostazol Dosing and Clinical Use in Peripheral Arterial Disease

Recommended Dosing and Administration

• The American College of Cardiology recommends a dose of 100 mg orally twice daily, taken 30 minutes before or 2 hours after breakfast and dinner to optimize absorption in patients with intermittent claudication. 6

Absolute Contraindications

• Heart failure of any severity is an absolute contraindication to cilostazol therapy, regardless of ejection fraction or clinical class. 6

Position in Treatment Algorithm

• Cilostazol is considered first‑line pharmacotherapy for lifestyle‑limiting claudication when supervised exercise therapy alone is insufficient. 6
• A therapeutic trial of cilostazol should be offered to all patients with lifestyle‑limiting claudication who do not have heart failure. 6

Alternative Pharmacologic Options

• Pentoxifycine (400 mg three times daily) is listed as a second‑line alternative with only marginal clinical effectiveness compared with cilostazol. 6

Cilostazol Dosing and Safety for Intermittent Claudication

Dosage Recommendations

• The recommended adult regimen for intermittent claudication is cilostazol 100 mg taken orally twice daily, with each dose administered at least 30 minutes before or at least 2 hours after meals; the dose should be reduced to 50 mg twice daily when co‑administered with CYP3A4 or CYP2C19 inhibitors【7】.
• In patients receiving CYP3A4 or CYP2C19 inhibitors, the United States guidance permits the reduced 50 mg twice‑daily dose, whereas European regulators contraindicate use altogether【7】.

Efficacy

• In randomized trials, cilostazol 100 mg twice daily produced a 40–60 % increase in maximal walking distance compared with placebo after 12–24 weeks of therapy【7】.
• Head‑to‑head comparisons demonstrated that the 100 mg twice‑daily regimen is significantly more effective than the 50 mg twice‑daily regimen for improving walking distance【7】.

Contraindications and Safety Warnings

• Cilostazol is absolutely contraindicated in any patient with heart failure, irrespective of NYHA class, left‑ventricular ejection fraction, or symptom status【7】【8】.
• The FDA has issued a black‑box warning for cilostazol because other phosphodiesterase‑III inhibitors (e.g., milrinone, vesnarinone) have been associated with increased mortality in heart‑failure populations【8】【9】.

Comparative Effectiveness

• Pentoxifylline 400 mg three times daily is considered second‑line therapy for claudication but provides only marginal clinical benefit, with outcomes comparable to placebo【8】【9】.
• Direct head‑to‑head trials showed that cilostazol significantly outperformed pentoxifylline, which did not differ from placebo in improving walking distance【8】.

Cardiovascular Safety Outcomes

• Long‑term safety data from trials enrolling >2,000 patients and follow‑up to 6 months showed cardiovascular death rates of 0.6 % with cilostazol versus 0.5 % with placebo, indicating no excess mortality risk【8】.
• Although cilostazol improves symptomatic walking ability, it does not reduce the incidence of myocardial infarction, stroke, or overall cardiovascular death【8】.

Guideline Summary for Cilostazol Use in Intermittent Claudication

Contraindications

• The American College of Cardiology states that cilostazol is absolutely contraindicated in any patient with heart failure of any severity, regardless of ejection fraction or NYHA class. 10

Monitoring and Safety

• Tolerance assessment should be performed 2–4 weeks after initiation to identify intolerable adverse effects. 10
• The most common adverse effects are headache (≈2.8‑fold higher incidence than placebo), diarrhea, abnormal stools, palpitations, and dizziness. 10
• ≈20 % of patients discontinue cilostazol within 3 months because of these adverse effects. 10
• Clinical benefit should be re‑evaluated at 3–6 months to decide whether long‑term therapy is warranted. 10

Efficacy for Intermittent Claudication

• Cilostazol improves claudication symptoms but does not reduce major cardiovascular ischemic events (myocardial infarction, stroke, or cardiovascular death). 10
• The sole FDA‑approved indication for cilostazol is symptom relief in intermittent claudication, with no proven cardiovascular protection. 10

Cardiovascular Safety

• Long‑term safety data from trials enrolling >2 000 patients show cardiovascular death rates of 0.6 % with cilostazol versus 0.5 % with placebo, indicating no excess mortality risk in patients without heart failure. 10

Use After Endovascular Therapy for Femoropopliteal Disease

• Cilostazol may be useful to reduce restenosis after endovascular therapy for femoropopliteal disease. 10
• In a blinded randomized controlled trial, cilostazol improved primary patency at 3 years after bare‑metal femoropopliteal stent placement. 10
• A meta‑analysis of 3 RCTs and 5 observational studies (total = 3 846 patients) demonstrated that cilostazol enhanced primary patency, lowered target‑lesion revascularization, and reduced major adverse limb events after femoropopliteal endovascular therapy. 10